rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AMRN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Amarin: 3 Key Takeaways for Long-Term Investors
      Nov 11Yahoo FinanceAMRN
      Amarin (AMRN) Q3 Results Recast Profit Story As Revenue Falls
      Oct 30Yahoo FinanceAMRN
      Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark
      Oct 29Yahoo FinanceAMRN
      Amarin Corp PLC (AMRN) Q3 2026 Earnings Call Highlights: First Profitable Quarter in Two Years ...
      Oct 28Yahoo FinanceAMRN
      Amarin: Q3 Earnings Snapshot
      Oct 28Yahoo FinanceAMRN
      Amarin (AMRN) Q3 2026 Earnings Call Transcript
      Oct 28The Globe and MailAMRN
      Amarin Returns to Quarterly Profit as Cost Reductions Offset 20% Revenue Decline
      Oct 28Yahoo FinanceAMRN
      What Amarin (AMRN) Said on Its Q3 Earnings Call
      Oct 28Yahoo FinanceAMRN
      Amarin Q3 2026 slides: profitability returns amid revenue decline
      Oct 28Investing.comAMRN
      Earnings call transcript: Amarin posts first profit in two years in Q3 2026
      Oct 28Investing.comAMRN
      Amarin Corp Q3 2026 Earnings Call Transcript
      Oct 28BenzingaAMRN
      Amarin’s icosapent ethyl shows survival benefit in cancer trial
      Oct 25Investing.comAMRN
      Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
      Oct 21Yahoo FinanceAMRN
      Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

      Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.

      Sep 9Yahoo FinanceAMRN
      Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026

      Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA) 2026 ESC/European Renal Association (ERA) Cardiovascular and Chronic Kidney Disease Guideline Further Reinforces the Clinical Evidence Supporting Icosapent Ethyl DUBLIN and BRIDGEWATER, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascula

      Aug 31Yahoo FinanceAMRN
      Amarin analysis links Vascepa adherence to greater, longer-lasting heart benefits (AMRN:NASDAQ)
      Aug 30Seeking AlphaAMRN
      Amarin to Present New REDUCE-IT and EPA Analyses at ESC Congress 2026

      Amarin Corporation plc (NASDAQ:AMRN) will present new REDUCE-IT and EPA analyses at the European Society of Cardiology Congress 2026, adding further research around icosapent ethyl, cardiovascular risk factors and potential mechanisms associated with eicosapentaenoic acid. The presentations, scheduled for August 28 through August 30 during the Munich conference, will examine areas including treatment adherence, longer-term outcomes, lipoprotein(a), coagulation biomarkers and cellular pathways re

      Aug 24Yahoo FinanceAMRN

      This is the newest page. Registered accounts read further back.